Gulbake Arvind, Jain Aviral, Jain Ashish, Jain Ankit, Jain Sanjay K
Arvind Gulbake, Center for Interdisciplinary Research, D.Y. Patil University, Kolhapur 416006, Maharashtra, India.
World J Gastroenterol. 2016 Jan 14;22(2):582-99. doi: 10.3748/wjg.v22.i2.582.
Colorectal cancer (CRC) is the third most common cancer diagnosed worldwide in human beings. Surgery, chemotherapy, radiotherapy and targeted therapies are the conventional four approaches which are currently used for the treatment of CRC. The site specific delivery of chemotherapeutics to their site of action would increase effectiveness with reducing side effects. Targeted oral drug delivery systems based on polysaccharides are being investigated to target and deliver chemotherapeutic and chemopreventive agents directly to colon and rectum. Site-specific drug delivery to colon increases its concentration at the target site, and thus requires a lower dose and hence abridged side effects. Some novel therapies are also briefly discussed in article such as receptor (epidermal growth factor receptor, folate receptor, wheat germ agglutinin, VEGF receptor, hyaluronic acid receptor) based targeting therapy; colon targeted proapoptotic anticancer drug delivery system, gene therapy. Even though good treatment options are available for CRC, the ultimate therapeutic approach is to avert the incidence of CRC. It was also found that CRCs could be prevented by diet and nutrition such as calcium, vitamin D, curcumin, quercetin and fish oil supplements. Immunotherapy and vaccination are used nowadays which are showing better results against CRC.
结直肠癌(CRC)是全球人类中诊断出的第三大常见癌症。手术、化疗、放疗和靶向治疗是目前用于治疗CRC的传统四种方法。将化疗药物特异性地输送到其作用部位将提高疗效并减少副作用。基于多糖的靶向口服给药系统正在被研究,以将化疗和化学预防剂直接靶向并递送至结肠和直肠。将药物特异性地递送至结肠可增加其在靶部位的浓度,因此需要较低的剂量,从而减少副作用。本文还简要讨论了一些新疗法,如基于受体(表皮生长因子受体、叶酸受体、麦胚凝集素、血管内皮生长因子受体、透明质酸受体)的靶向治疗;结肠靶向促凋亡抗癌药物递送系统、基因治疗。尽管CRC有很好的治疗选择,但最终的治疗方法是预防CRC的发生。还发现可以通过饮食和营养如钙、维生素D、姜黄素、槲皮素和鱼油补充剂来预防CRC。如今使用的免疫疗法和疫苗接种对CRC显示出更好的效果。